Key result
Short-term treatment with levosimendan, dobutamine, or nitroglycerin in acute decompensated heart failure showed no significant difference in serial cTnI changes.
Why the study?
Does levosimendan or dobutamine compared to nitroglycerin reduce myocardial injury in patients with acute decompensated heart failure?
Cohort (n=122)
Does levosimendan or dobutamine compared to nitroglycerin reduce myocardial injury in patients with acute decompensated heart failure?
Short-term use of levosimendan, dobutamine, and nitroglycerin showed no significant difference in serial changes of cTnI levels, though levosimendan showed favorable effects on NT-proBNP and functional parameters in ADHF.
Answers are grounded in this paper and cite their sources.
No basis to prefer agents for limiting injury in ADHF; leaves open effects on clinical outcomes.
BACKGROUND: Cardiac troponins (cTn) are reliable and the most sensitive biomarker in the setting of acute decompensated heart failure (ADHF). Acute decompensated heart failure is usually associated with worsening chronic heart failure, and it may be caused by ongoing minor myocardial cell damage that may occur without any reported precipitating factors. METHODS: We compared the short-term effect of levosimendan (LEV), dobutamine (DOB), and vasodilator treatment (nitroglycerin [NTG]) on myocardial injury with hemodynamic, neurohumoral, and inflammatory indicators. One hundred twenty-two patients with a mean age of 66 ± 9 years were treated with LEV (n = 40), DOB (n = 42), and NTG (n = 40) and examined retrospectively. Blood samples (cTnI, N-terminal probrain natriuretic peptide [NT-proBNP], highly sensitive C-reactive protein [HsCRP], and others), left ventricular ejection fraction (LVEF), systolic pulmonary artery pressure (sPAP), and 6-minute walk distance (6MWD) were compared before and after treatment. RESULTS: At admission, detectable levels of cTnI were observed in 53% of patients (≥0.05 ng/mL). Serial changes in the mean cTnI levels were not significantly different between the groups (LEV 0.04 ± 0.01 to 0.03 ± 0.01 ng/mL; DOB 0.145 ± 0.08 to 0.08 ± 0.03 ng/mL; NTG 0.1 ± 0.03 to 0.09 ± 0.02 ng/mL; overall P = .859). Favourable effects on the NT-proBNP, sPAP values, LVEF, 6MWD, and HsCRP were observed overall, especially in the LEV groups. CONCLUSION: Beneficial effects of short-term use of LEV, DOB, and NTG on ongoing myocardial injury were demonstrated. These findings can be attributed to the anti-ischemic properties as well as the hemodynamic, neurohumoral, and functional benefits from the positive inotropes, especially LEV, in patients with ADHF.
No takes yet. Share an insight, caveat, or question.
Gencer et al. (2016) conducted a cohort in Acute decompensated heart failure (ADHF) (n=122). Levosimendan vs. Dobutamine and Nitroglycerin was evaluated on Serial changes in mean cTnI levels (p=0.859). Short-term treatment with levosimendan, dobutamine, or nitroglycerin in acute decompensated heart failure showed no significant difference in serial cTnI changes.
Synapse has enriched 10 related papers. Consider them for comparative context: